Journal
PROGRESS IN CARDIOVASCULAR DISEASES
Volume 59, Issue 2, Pages 107-118Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcad.2016.08.003
Keywords
Triglyceride; Hypertriglyceridemia; Hyperlipidemia; Cardiovascular disease
Categories
Funding
- NHLBI NIH HHS [P01 HL092969] Funding Source: Medline
Ask authors/readers for more resources
Cholesterol reduction has markedly reduced major cardiovascular disease (CVD) events and shown regression of atherosclerosis in some studies. However, CVD has for decades also been associated with increased levels of circulating triglyceride (TG)-rich lipoproteins. Whether this is due to a direct toxic effect of these lipoproteins on arteries or whether this is merely an association is unresolved. More recent genetic analyses have linked genes that modulate TG metabolism with CVD. Moreover, analyses of subgroups of hypertriglyceridemic (HTG) subjects in clinical trials using fibric acid drugs have been interpreted as evidence that TG reduction reduces CVD events. This review will focus on how HTG might cause CVD, whether TG reduction makes a difference, what pathophysiological defects cause HTG, and what options are available for treatment. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available